OBR Daily Commentary - Breast

forumImage

Next Big Thing in ER+ Breast Cancer: For Early-Stage Too?

(Medscape Medical News) Dec 8, 2016 - Two agents that inhibit cyclin-dependent kinases 4 and 6 (CDK4/6) have yielded unprecedented results in progression-free survival in clinical trials involving postmenopausal women with estrogen-receptor (ER) positive, HER2-negative metastatic breast cancer.

Dean Gesme, MD (Posted: December 10, 2016)

quotesIt is encouraging to see three competing CDK 4/6 inhibitors soon to be available. With the huge potential market consisting of ER + great cancer, it will be a great case study in market pricing --- I.e. competitive capitalism vs collaborative market maintainance.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

Memorial Sloan Kettering to Offer DigniCap® Scalp Cooling Device in New York Metro Area Locations

(Yahoo! Finance) Feb 13, 2017 - Dignitana AB, the world leader in medical scalp-cooling technology, announced today that the DigniCap® scalp cooling system, which was cleared in December 2015 by the U.S. FDA to effectively reduce the likelihood of chemotherapy-induced hair loss in women with breast cancer, will be available at all Memorial Sloan Kettering Cancer Center (MSK) facilities that treat breast cancer.

William Harwin MD (Posted: February 15, 2017)

quotesAt Florida Cancer Specialists we have been using DigniCap for several months at 3 of our site and it does appear to be a real advance in preventing alopecia from chemotherapy. I just completed treatment with 6 cycles of TCH + Pertuzumab in a woman with breast cancer with a full head of hair at completion of treatment. The problems with DigniCap are the cost and lack of insurance reimbursement. It may not be fully effective in all patients especially with an Adriamycin regimen.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

No Details Yet, But Genentech Drug Combo Wins in Big Breast Cancer Study

(Xconomy San Francisco) Mar 2, 2017 - There may be a new standard of care coming for a large portion of women with breast cancer who have had surgery to remove their tumors.

Dean Gesme, MD (Posted: March 02, 2017)

quotesAphinity is expected to be practice changing for Her2 positive early breast cancer patients not already treated with these agents in the neoadjuvant setting. I anticipate this to be a Plenary presentation at ASCO 2017.quotes

Read Article arrow
Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...